Cardiac Magnetic Resonance Imaging and Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

William J. McKenna, MD; Sherif F. Nagueh, MD

Predicting the future is always hard, and no more so than in a common disease like hypertrophic cardiomyopathy (HCM), which is usually associated with few if any symptoms yet can be a rare cause of sudden death in young people. For decades, the approach to the identification of individuals at high risk has been based on a semiquantitative estimation of relative risk derived from the summation of a small number of clinical markers. There are no prospective data on which to judge the clinical efficacy of this approach, but retrospective analyses suggest that it is only modestly predictive of future events. Similar dilemmas in other areas of medicine have been addressed with sophisticated risk models designed to estimate absolute risks. Until recently, the approach in HCM has been very different. Most investigators have hunted for new and ever more sophisticated tools that provide a window into the complex substrate that causes ventricular arrhythmia. In this issue of Circulation, Chan et al present a study using cardiac magnetic resonance imaging (CMR) and suggest that it improves on current risk prediction methods. Specifically, they suggest that CMR assessment of late gadolinium enhancement (LGE) provides the following: a statistically stronger predictor of sudden cardiac death events than each of the individual conventional risk factors used in HCM; a "unique opportunity" to identify sudden cardiac death risk in asymptomatic HCM patients, previously thought to be at low risk for lethal ventricular tachyarrhythmias; and the ability to identify unrecognized high-risk patients who could potentially benefit from implantable cardioverter-defibrillator (ICD) therapy. Given the high stakes associated with the decision to implant an ICD in young and often otherwise healthy people, we must be sure that the data are robust enough to change clinical practice.

Current American and joint American/European guidelines for sudden death prevention are based on 5 risk factors: syncope, family history of premature sudden death, nonsustained ventricular tachycardia during 24-hour ECG, severe left ventricular hypertrophy, and an abnormal blood pressure response during upright exercise. Patients without these features are at very low risk of lethal events, and their survival does not differ from that of matched non-HCM control populations. The challenge is to improve the predictive accuracy to maximize the benefit-to-risk ratio of an ICD. A step toward improved targeting of therapy is provided in a recent multicenter study of >3500 patients that uses a validated risk tool to calculate individualized 5-year estimates of sudden cardiac death risk. The model confirms the very low risk of death in patients without validated risk markers and provides a new benchmark against which other putative risk predictors can be measured.

CMR is evolving into an important diagnostic tool in myocardial disease. Evaluation of LGE and now native T1 mapping and extracellular volume quantification permit differentiation of amyloidosis, edema/inflammation, iron overload, and Fabry disease from HCM. The extent of LGE has been associated with HCM heart failure–related outcomes and in cross-sectional studies has been associated with established risk factors for sudden death. Previous outcome studies with fewer patients and events have failed to demonstrate the prognostic utility of LGE for the identification of patients with HCM at risk of sudden death. Two recent studies have evaluated LGE as a predictor of sudden death events in larger cohorts. Chan et al studied 1293 patients, of whom 20 died suddenly or survived a cardiac arrest (1.5%) and 17 had an appropriate ICD discharge (1.3%) during a median of 3.3 years. This was a prospective study in that follow-up was from the time CMR was performed, and all studies were rigorously assessed in a CMR core laboratory, a particular strength of the study given the recognized intercenter variability in LGE measurements. Risk evaluation, however, was retrospective, and a major weakness was the absence of 24-hour ECG in 24% of the apparently low-risk cohort who had no other risk factors; this was a consequence of the study design in which Holter was obtained "at the discretion of investigators at each institution." In contrast to the work by Chan et al, a study by a group of European HCM investigators found the extent of LGE to be a strong univariate predictor of sudden cardiac death, which was not maintained after adjustment for left ventricular ejection fraction.

Perhaps the most important claim in the study by Chan et al is the ability of CMR to identify patients who would be classified as low risk with current methods who go on to develop events. The statistical analysis appears to support this statement (Tables 3–5 and Figures 2 and 3), but the raw data (Table 2) do not. Setting aside for a moment appropriate ICD discharge as an end point, 20 patients died suddenly or experienced a cardiac arrest. Of these, 1 had extensive LGE as a percentage of mass (40%) with impaired systolic function (ejection fraction, 31%), 3 had small amounts of LGE...
larly patients otherwise judged to be at low risk.” The data
den cardiac death event risk among HCM patients, particu-
larly those with a high number of risk markers (≥2 risk factors).
This is not a low-risk cohort, and the apparent target
classification of CMR study. Only 4 patients had
no conventional risk factors (However, the Holter data are not
presented; only the fact that they received a Holter is men-
tioned). Of these 4 patients, 3 had extensive LGE, and LGE
may be added value. Similarly, the patients with a single risk
factor may receive added value from evaluation of LGE, but
study design and size preclude this conclusion. There were
insufficient analogous patients to enable analysis of the poten-
tial role for CMR to refine risk.

A major limitation of being a “prospective retrospective”
study is the inevitable exclusion from analysis of 376 patients
(23%) because of prior ICD implantation. The resultant cohort
is enriched for low-risk patients and new patients undergo-
ing preliminary or repeat risk stratification. This led to a low
annual sudden death rate (0.5%) and, within the cohort who
subsequently received ICDs, a low ICD discharge rate (0.4%).
The low number of events affects statistical analysis in which
the number of events limits the number of risk markers that
can legitimately be evaluated. In this study, 4 conventional
risk markers (syncope, adverse family history, nonsustained
ventricular tachycardia, severe left ventricular hypertrophy)
were collapsed into the analysis as a single continuous vari-
able. The use of this statistical approach highlights the need
for more robust data sets with larger numbers of events.

The authors conclude their article with the following:
“Extensive LGE measured by quantitative contrast-enhanced
CMR provides additional information for assessing sud-
en death risk in patients with hypertrophic cardiomyopathy.
The incidence of dilated cardiomyopathy is higher than that of
hypertrophic cardiomyopathy, and the pathophysiology and
treatment of these conditions differ significantly. Therefore,
additional studies are needed to determine the role of LGE in
decision-making for patients with dilated cardiomyopathy.

Disclosures
None.

References
   S, McKenna WJ, Elliott PM. A validation study of the 2003 American
   College of Cardiology/European Society of Cardiology and 2011
   American College of Cardiology/European Society of Cardiology/American Heart Association
   risk stratification and treatment algorithms for sudden cardiac death in
   JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi
   M, Cechi F, Tomberi B, Spirti P, Formisano F, Biagini E, Rapezzi C,
   De Luca CN, Antonucci E, Cok EF, Hong SN, Gibbons CM, Manning WN,
   Appelbaum E, Maron MS. Prognostic value of quantitative contrast-
   enhanced cardiovascular magnetic resonance for the evaluation of sud-
   2014;130:484–495.
   SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA,
   Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis
   and treatment of hypertrophic cardiomyopathy: a report of the American
   College of Cardiology Foundation/American Heart Association Task Force
   on Practice Guidelines: developed in collaboration with the American
   Association for Thoracic Surgery, American Society of Echocardiography,
   American Society of Nuclear Cardiology, Heart Failure Society of
   America, Heart Rhythm Society; Society for Cardiovascular Angiography
4. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ,
   Seidman CE, Shah PM, Spencer WH, Spirti P, Ten Cate FJ, Wigle ED,
   Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos
   G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR,
   O’Rourke RA, Pohost GM, Schofill RS, Tracy CM, Winters WL, Klein
   WS, Priori SG, Allessandrini C, de Braganca A, Blomström-Lundqvist C,
   Cianferrini G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S,
   Torbicki A. American College of Cardiology/European Society of
   Cardiology clinical expert consensus document on hypertrophic car-
diomyopathy: a report of the American College of Cardiology Foundation
   Task Force on Clinical Expert Consensus Documents and the European
   Society of Cardiology Committee for Practice Guidelines. Eur Heart J.


**Key Words:** Editorials - cardiomyopathy, hypertrophic - death, sudden, cardiac - magnetic resonance imaging
Cardiac Magnetic Resonance Imaging and Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
William J. McKenna and Sherif F. Nagueh

Circulation. 2014;130:455-457
doi: 10.1161/CIRCULATIONAHA.114.010977
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/130/6/455

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/